Collaborations Between Biotech And Pharmaceutical Companies: New Agreements, Feb. 24-April 28, 2005#
Biotech Co.* | Pharma Co. | Type/Product Area | Terms/Details (Date) |
| | |||
Affymetrix | bioMerieux SA (France) | bioMerieux gained long-term and comprehensive access to Affymetrix's GeneChip technology | bioMerieux will use the technology for in vitro diagnostic tests for breast cancer; it also got an option to expand the deal into other cancer areas; terms were not disclosed (4/5) |
Alliance | Beijing Double-Crane Pharmaceutical Co. Ltd. (China) | They entered a memorandum of understanding on a deal to develop Oxygent in China | Alliance would be entitled to up-front, milestone and royalty payments if a license deal is executed (4/5) |
Ark | Boehringer Ingelheim International GmbH (Germany) | BI got rights to use Ark renin-angiotensin system technologies in its products | Ark gets an up-front payment and could receive milestone payments and royalties on sales of cardiovascular products covered by its patents (4/1) |
Avanir | Novartis AG (Switzerland) | Worldwide deal to develop small-molecule drugs targeting macrophage migration inhibitory factor for treating inflammatory diseases | Avanir is eligible to receive more than $200M in up-front and development, regulatory and sales milestone payments, and gets up to $2.5M per year for four years in research payments; it also would get royalties on sales (4/28) |
BioCurex Inc. | Abbott Laboratories | Abbott licensed RECAF technology, a cancer biomarker that may be useful in new diagnostic tests | BioCurex gets up-front fees, development milestones and royalties on any sales; Abbott gets worldwide, semi-exclusive rights (3/29) |
BioFocus plc | Eli Lilly and Co. | Deal to discover compounds that target nuclear hormone receptors | The deal involves use of BioFocus' high- throughput expertise; BioFocus will get research fees that increase as the program progresses (3/2) |
Biolex Inc.* | Centocor Inc. (unit of Johnson & Johnson) | Deal under which Biolex will manufacture and help advance certain Centocor proteins using the Biolex LEX System | Biolex, which will advance up to 10 proteins, gets an up-front payment and potential milestones and royalties; it also gets funding over three years to support scale-up of parts of the system, and J&J will make an equity investment in Biolex's next financing (3/21) |
Cangene Corp. | Baxter Healthcare Corp. | Baxter assumed exclusive rights to market Cangene's WinRho SDF immune globulin product in the U.S. | Baxter already markets the product for immune thrombocytopenic purpura in the UK, and intends to launch it in 10 other European countries; terms were not disclosed (3/29) |
Cellzome Inc.* | Ortho-McNeil Pharmaceutical Inc. (unit of Johnson & Johnson) | Collaboration to identify new medicines for treating Alzheimer's disease | Cellzome is providing access to its AD technology in exchange for a technology access fee and research funding for two years, as well as potential milestone and royalty payments (3/16) |
Cenix | Schering AG (Germany) | Research service agreement to accelerate Schering's target discovery and validation efforts | Cenix will validate collections of candidate genes identified by Schering as possible therapeutic drug targets; terms were not disclosed (2/28) |
CepTor Corp. | JCR Pharmaceuticals Co. Ltd. (Japan) | JCR got a 15-year license to market CepTor's muscular dystrophy product Myodur in the Pacific Rim | The deal entitles CepTor to equity payments, milestone payments and double-digit royalties on sales in the Pacific Rim (3/2) |
ChemBridge | UCB Group SA (Belgium) | ChemBridge will provide chemistry services to help UCB discovery efforts | Further details and financial terms were not disclosed (3/2) |
Coley | Pfizer Inc. | Worldwide deal to develop and sell Coley's ProMune, a Toll- ike receptor 9 agonist, for cancer indications | Coley gets $50M up front and up to $455M more in milestone payments, plus royalties on any sales; Pfizer may invest up to $10M in Coley upon Coley's initial public offering (3/24) |
Collegium | URL/Mutual Pharmaceutical Co. | Deal to develop and sell an undisclosed product | Collegium will do early work on the compound, then transfer responsibilities to URL; Collegium is entitled to milestone and royalty payments (4/20) |
Compugen Ltd. | Novartis AG (Switzerland) | Compugen will develop a platform for research and analysis of biological data on biological interaction networks | Novartis will make a one-time payment for the information, and get sole rights to the project results; Compugen retains rights to the research and discovery systems developed through the collaboration (4/19) |
Crucell NV (the | Mitsubishi Pharma Corp. (Japan) | Mitsubishi got rights to use the PER.C6 cell line for producing certain recombinant therapeutic proteins | Mitsubishi will make an up-front payment and pay annual maintenance fees; further terms were not disclosed (3/23) |
Crucell NV (the | JCR Pharmaceuticals Co. Ltd. (Japan) | JCR got rights to use the PER.C6 cell line for producing certain recombinant therapeutic proteins | JCR will make a research license payment and annual maintenance fees; further terms were not disclosed (3/10) |
Cyclacel Group | Altana Pharma AG (Germany) | Cyclacel will use its expertise in cell division to identify molecular targets of specific Altana drug candidates | Terms of the deal were not disclosed (3/16) |
Cyntellect | Daiichi Pharmaceutical Co. Ltd. (Japan) | Daiichi will use Cyntellect's high-throughput cell-imaging and cell-manipulation technologies in drug discovery | Cyntellect will design and run LEAP cell- based assays against a Daiichi compound collection; terms of the deal were not disclosed (3/30) |
Cytomedix | DePuy Spine Inc. (unit of Johnson & Johnson) | Second deal between the companies gave DePuy rights to autologous platelet releasate therapy | The license excludes treatment of chronic wounds; also, DePuy's existing license for spinal, orthopedic and neurosurgical applications will be converted to a nonexclusive license; terms were not disclosed (3/8) |
Depomed Inc. | Boehringer Ingelheim Pharmaceuticals Inc. (Germany) | Depomed will develop a controlled-release formulation of an undisclosed compound for BI | Depomed will apply its Gastric Retention technology to the BI compound; a license agreement could follow (4/28) |
Eiffel | Undisclosed U.S. company | They signed a second deal in three months; Eiffel will use its re-engineering technology to formulate an asthma drug | Eiffel will receive a $75,000 up-front payment for the two-month study; further licensing deals could ensue (2/28) |
Elixir | Bristol-Myers Squibb Co. | Elixir got exclusive rights to BMS's growth hormone secretagogue BMS-604992 and five related compounds | BMS gets an up-front license fee comprised of cash and stock, and is entitled to milestone and royalty payments; the program is at the preclinical stage (4/28) |
ESBATech AG* | Novartis Pharma AG (Switzerland) | Collaboration for drug discovery in the area of receptor tyrosine kinase inhibitors | Novartis gets nonexclusive access to ESBA- Tech's cellular high-throughput technology under undisclosed terms (3/31) |
Evotec OAI | Mitsubishi Pharma Corp. (Japan) | Evotec will support the advancement of compound hit series for Mitsubishi drug targets | Terms of the medicinal chemistry agreement were not disclosed (2/28) |
4SC AG* | Schwarz Pharma AG (Germany) | Collaboration to develop hits against targets that they identified in a pilot project | 4SC will use its technologies to develop pharmaceutical leads; 4SC gets research funding and is entitled to milestone payments and revenue sharing (4/5) |
GeneGo Inc.* | NV Organon (the Netherlands) | Organon licensed GeneGo's MetaCore platform for mining high-throughput experimental data | Organon will use MetaCore in preclinical research across various therapeutic areas (4/19) |
Gene Network | Johnson & Johnson Pharmaceutical Research & Development LLC | GNS will provide pathway inference technology and data- driven computer modelsto J&J | The technology will help determine pathways data for a J&J preclinical oncology compound; terms of the deal were not disclosed (3/7) |
Genentech | Ipsen SA (France) | Deal to develop sustained- release formulations of Genentech's recombinant human growth hormone | The alliance supplements an existing deal under which Ipsen markets NutropinAq in Europe and has rights elsewhere except North America and Japan; terms of the deal were not disclosed (3/21) |
Genome | bioMerieux SA (France) | Genome Express will carry out bacterial analyses for bioMerieux | Terms of the deal were not disclosed (3/4) |
GenWay | Beckman Coulter Inc. | BC got access to GenWay's IgY microbead technology, which can be used in detecting biomarkers and drug targets | The exclusive license agreement also provides a basis for future collaboration on development of GenWay's IgY capture technology; terms were not disclosed (3/31) |
Gilead | Japan Tobacco Inc. (Japan) | Gilead got exclusive rights outside Japan to develop an HIV integrase inhibitor (JTK-303) | JT gets $15M up front and up to $90M in milestone payments, as well as royalties on any sales; Gilead plans to start Phase I/II trials by mid-2005 (3/22) |
Helix | Apotex Group (Canada) | Helix will identify and characterize a lead formulation for Apotex's topical therapeutic product line | The work will be done by Helix subsidiary PharmaDerm Laboratories; terms were not disclosed (2/28) |
Iceland | Roche Diagnostics (Switzerland) | Collaboration to analyze patient samples for discovery of cancer biomarkers | IGC gets access to certain gene-expression data and support for further biological characterization of the samples in Iceland; terms of the deal were not disclosed (3/17) |
Icoria Inc. | Syngenta Ltd. | Syngenta got exclusive rights to develop 30 Icoria compounds believed to be active fungal inhibitors | Syngenta will evaluate the compounds over 18 months, then could develop them in agricultural, human and other applications; Icora gets an up-front payment and could receive milestone and royalty payments (2/28) |
Ionix | Reckitt Benckiser Healthcare (UK) | Collaboration on Ionix's IX- 003 for post-operative pain and the preclinical products IX- 004 and IX-1005, for pain and opiate addiction | All three products are based on intranasal delivery of RBH's buprenorphine; Ionix is eligible for milestone and royalty payments, and retains an option to co-promote IX-1003 in the U.S. (2/28) |
Intercell AG | Biological E. Ltd. (India) | Deal under which Biological E. will manufacture and sell Intercell's Japanese encephalitis vaccine in Asia | The companies said they intend to work together in the future on other vaccines; terms were not disclosed (3/18) |
KineMed Inc.* | Sosei Co. Ltd. (Japan) | KineMed will screen a number of Sosei molecules to determine their potential in new indications | KineMed will use its in vivo KineMarker assays in the deal, terms of which were not disclosed (4/13) |
LifeSpan | Pfizer Inc. | Deal to develop an automated pathology system for evaluation of tissue specimens in preclinical studies | The system developed by LifeSpan uses enhanced image capture and artificial intelligence computer analysis software; terms were not disclosed (3/3) |
Locus | Scios Inc. (unit of Johnson & Johnson) | Deal under which Locus will apply its molecular fragment technology focused on protein kinases | Locus will design for Scios new chemical classes of protein kinase inhibitors under undisclosed terms (3/14) |
Lorus | Sumitomo Pharmaceuticals Co. Ltd. and Koken Co. Ltd. (both Japan) | Deal to develop Lorus' antisense cancer drug GTI-2601 with the partners' collagen-based delivery system | The companies will jointly own resulting compounds; terms of the deal were not disclosed (4/5) |
MedImmune | Abbott Laboratories | Abbott will market Numax, MedImmune's anti-RSV monoclonal antibody in Phase III trials, outside the U.S. | Abbott also will continue to market Synagis under the amended deal; MedImmune has the option to co-promote Numax in up to seven countries outside the U.S.; it retained rights in the U.S. (2/28) |
MerLion | Sankyo Co. Ltd. (Japan) | Three-year collaboration under which MerLion will isolate new drug leads for Sankyo | Sankyo would develop and commercialize resulting products; terms of the deal were not disclosed (4/20) |
MorphoSys | Boehringer Ingelheim GmbH (Germany) | An expanded collaboration gives BI an option to several exclusive licenses on new therapeutic antibody programs | They already are developing two antibody programs; BI also got access to MorphoSys' HuCAL Gold library; MorphoSys gets a technology access fee, annual license fees and optional R&D funding over five years, as well as potential milestones and royalties (3/17) |
Neose | BioGeneriX AG (Germany; part of the Ratiopharm Group) | License and option deal to use Neose's GlycoPEGylation technology to develop a long-acting form of a marketed therapeutic protein | The deal follows a previous supply and option agreement; Neose will get further up-front and research payments, and could get up to $61.5M in milestone payments, as well as royalties on any sales (4/28) |
Novavax Inc. | Ranbaxy Laboratories Inc. (India) | Deal to evaluate a transdermal product formulated using Novavax's micellar nanoparticle technology | Novavax will get funding to complete a proof-of-concept study, which could be followed by a commercialization and development agreement (3/16) |
Nuevolution | Novo Nordisk A/S (Denmark) | Collaboration to discover drug leads for targets provided by Novo | Nuevolution will use its Chemetics technology in the effort; terms of the deal were not disclosed (4/12) |
Nuvelo Inc. | Kirin Brewery Co. Ltd. (Japan) | Collaboration to advance the preclinical growth factor NU206, which was developed under an existing alliance | Nuvelo will lead development; it gets a $2M up-front payment, and will pay 60% of the costs and get 60% of the revenues from the program (4/4) |
Osel Inc.* | Miyarisan Pharmaceutical Co. Ltd. (Japan) | Osel gained exclusive rights in North America and Europe to MIYA-BM | The oral product is approved in Japan for treating antibiotic-induced gastrointestinal disorders; terms of the deal were not disclosed (3/2) |
Oxford Genome | Bayer HealthCare AG (Germany) | Oxford will evaluate candidate biomarkers that may have applications in breast cancer | Oxford gets funding for the program under which it will apply proteomics technologies, and potential milestone payments (3/16) |
Pepscan Systems | Solvay Pharmaceuticals (Belgium) | The companies will identify novel peptide substrates for a series of Solvay proteases | Terms of the research agreement for the de-orphanization of proteases were not disclosed (3/8) |
Perlegen | Mitsubishi Pharma Corp. (Japan) | Perlegen got rights outside of Asia to the PPAR agonist, MCC-555, a product in the clinic for treating diabetes and other metabolic disorders | Mitsubishi gets an up-front payment and could receive cash and equity milestone payments; it also gets rights to use predictive genetic markers identified by Perlegen; they each would pay royalties on sales (4/12) |
PharmaDesign | Novartis AG (Switzerland) | Novartis licensed a GPCR peptide ligand library designed by PDI | Terms of the deal were not disclosed (4/20) |
Pieris | Syngenta AG (Switzerland) | Collaboration to develop an anticalin-based drug from Pieris for an undisclosed indication | Pieris is responsible for research and for providing the active drug; Syngenta is responsible for development and commercialization; terms were not disclosed (4/13) |
Power3 Medical Products Inc. (OTC BB:PWRM) | New Horizons Diagnostics Corp. | Collaboration to develop antibody-based diagnostics for neurodegenerative diseases | The work will involve protein biomarkers from Power3; terms of the deal were not disclosed (3/28) |
Procyon | Medicorp Inc. (Canada) | Medicorp got exclusive rights to develop and sell PSP94-based test kits | Medicorp will fund future development; they will share revenues from sales of test kits, and from sublicensing deals (3/2) |
Regenera Ltd. | Alcon Manufacturing Ltd. | Alcon licensed a product used to assist in visualization of vitreous fluid during a vitrectomy | Regenera gets an up-front payment and is entitled to milestone and royalty payments (double-digit in the U.S.) (4/7) |
Savient | Ferring Holding SA (Switzerland) | They entered a co-promotion deal on Nuflexxa as part of Savient's divestiture of its global biologics manufacturing business to Ferring | Savient will establish a sales force for the co-promotion effort, and get 50% of the global revenue from the approved sodium hyaluronate product above certain revenue thresholds; Ferring is paying $80M in cash over two years for the manufacturing busi- ness (3/23) |
Senetek plc | Signet Laboratories Inc. | They finalized a deal under which Signet will manufacture and market monoclonal antibodies licensed to Senetek | Signet will get a share of the revenues; the deal finalizes an amendment to an April 2004 deal (4/7) |
Serono SA | Rosetta Biosoftware (unit of Merck & Co. Inc.) | Serono licensed use of the Rosetta Resolver system | Serono gets rights to the gene-expression data analysis system under undisclosed terms (2/28) |
7TM Pharma | Procter & Gamble Pharmaceuticals Inc. | Collaboration to research the use of therapeutic angiogenesis to identify candidates for treating vascular diseases | P&G got exclusive rights to molecules derived from the program in exchange for an up-front fee, potential milestone payments and royalties on any sales; 7TM retained co-promotion rights in Scandinavia (4/12) |
SkyePharma | Mundipharma International Holdings Ltd. (UK) | Deal under which Mundipharma will market and distribute DepoBupivacaine in Europe and elsewhere excluding the U.S., Canada and Japan | SkyePharma gets $10M up front and up to $20M toward Phase III trials; it also is entitled to development and sales milestones that could bring total payments to $80M; SkyePharma would get 30% to 35% of sales, out of which it would pay for manufacturing (4/19) |
Sunesis | Bristol-Myers Squibb Co. | Sunesis licensed all rights to the cancer drug BMS-387032 (now SNS-032), a cyclin-dependent kinase inhibitor, and any related compounds | BMS gets an up-front equity stake of $8M in Sunesis, and up to $29M in cash and equity milestone payments for the first approval; other milestones could total $49M million; BMS also would get royalties on sales (4/28) |
Symbollon | Bioaccelerate Holdings Inc. | Worldwide license and co-marketing deal for IoGen, a Symbollon product for treating cyclic mastalgia | Bioaccelerate will fund ongoing Phase III development, and would commercialize the product; they would share any resulting profits (4/13) |
Theravance | GlaxoSmithKline plc (UK) | GSK exercised its option to license Theravance's inhaled bifunctional, muscarinic antagonist/beta2 agonist program | Theravance could get up to $252M in up- front and milestone payments, if the program has both single-agent and combina- tion products; it is the third respiratory program GSK licensed from Theravance (3/21) |
TorreyPines | Eisai Co. Ltd. (Japan) | They entered a research agreement involving drug discovery for Alzheimer's disease | Eisai has exclusive rights of first negotiation for validated compounds discovered through the research; development deals could follow (3/18) |
Tranksaryotic | Shire Pharmaceuticals Group plc (UK) | Shire got rights to manufacture and distribute Dynepo outside of North America | The license will take effect only if Shire's planned $1.6B acquisition of TKT does not occur for specified reasons (4/21) |
Vectura Group | Novartis AG (Switzerland) | Novartis gained rights to the two companies' AD 237, as a monotherapy and with up to $172.5M in milestone payments, as QAB149, for treating chronic obstructive pulmonary disease | Arakis and Vectura each will get $15M up front; they each also are eligible to receive well as royalties on any sales (4/13) |
VirtualScopics | Wyeth Pharmaceuticals | VirtualScopics will provide analytical and other imaging services to Wyeth | The services will be used in a Phase I trial of a product being studied for muscle wasting conditions; terms were not disclosed (3/14) |
Xencor Inc.* | Eli Lilly and Co. | Lilly exercised its option under a February 2004 deal to develop one or more proteins created by Xencor | Xencor gets an up-front license fee and is eligible to receive milestone payments, as well as royalties on any sales (4/13) |
Xenova Group | PharmaEngine Inc. (Taiwan) | PharmaEngine licensed rights to the brain cancer product TransMID in China and South Korea | Xenova gets an up-front payment, as well as potential milestone payments and royalties on any sales; it also will supply the product (4/13) |
Zealand | Wyeth Pharmaceuticals | Three-year expansion of an alliance to develop gap junction-modifying drugs for cardiovascular diseases | The alliance followed a 2003 license deal for the co- development of ZP123, a drug being developed for arrhythmias; they now will work on other compounds, and Wyeth got rights to evaluate Zealand's compound library; terms were not disclosed (3/4) |
| | |||
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; ATX = Austrian Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | |||